Trial Profile
A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Large granular lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 07 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 07 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 16 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.